Hematology/Oncology

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]

By afschroeder • June 13, 2026

Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.

By afschroeder • June 13, 2026

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Practical approach to MRD testing in breast cancer: Q&A. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):11-15. PMID: 42283709.

By afschroeder • June 13, 2026

Wander SA, Weipert CM, Cabel L, Liao J, Zhang N, Safonov A, Bardia A, Razavi P. Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6[...]

By afschroeder • June 13, 2026

Aggarwal H, Gupta N, Sengupta A, Sarkar A, Mylavarapu S, Pires IS, Saha T, Sarkar B, Kulkarni A, Mahajan VS, Goyal L, Bardia A, Fahrner[...]

By afschroeder • June 13, 2026

Keramida K, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Dent S, Drakaki A, Fuster JJ, Mamas MA, Okwuosa T, Scarfo L, Van Der Meer[...]

By afschroeder • June 12, 2026

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan[...]

By afschroeder • June 11, 2026

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

By afschroeder • June 11, 2026

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]

By afschroeder • June 10, 2026

Bansil S, Lai SY, Lo AE, Dietz R Jr, Reed JP. A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That[...]

By afschroeder • June 9, 2026